Atossa Therapeutics Issues Letter To Shareholders From Steven Quay, M.D., Ph.D., The Company's President And Chief Executive Officer
Portfolio Pulse from Benzinga Newsdesk
Atossa Therapeutics, Inc. (NASDAQ:ATOS), a biopharmaceutical company, issued a shareholder letter from CEO Steven Quay highlighting progress in 2023. Four Phase 2 trials of (Z)-endoxifen are underway, with primary data expected in the second half of the year. The Karisma-Endoxifen trial for breast density reached full enrollment. A federal law effective September 10 will require mammography facilities to notify patients about breast density. Atossa also initiated research with Weill Cornell Medicine on triple-negative breast cancer (TNBC). The company has a strong balance sheet with $94 million in cash as of September 30, 2023, and extended its share repurchase program through December 31, 2024.

January 09, 2024 | 1:46 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Atossa Therapeutics reports significant progress in 2023 with ongoing Phase 2 trials of (Z)-endoxifen, strong financials, and an extended share repurchase program.
The positive update on clinical trials and the strong financial position, coupled with the share repurchase program, are likely to be viewed favorably by investors, potentially leading to a short-term positive impact on ATOS stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100